C
Carl-Fredrik Burman
Researcher at AstraZeneca
Publications - 40
Citations - 814
Carl-Fredrik Burman is an academic researcher from AstraZeneca. The author has contributed to research in topics: Population & Hazard ratio. The author has an hindex of 15, co-authored 36 publications receiving 682 citations. Previous affiliations of Carl-Fredrik Burman include Chalmers University of Technology.
Papers
More filters
Journal ArticleDOI
A recycling framework for the construction of Bonferroni-based multiple tests.
TL;DR: Bonferroni-based multiple testing procedures (MTPs) are described as strategies to split and recycle test mass, and whenever a null hypothesis is rejected, the part of alpha allocated to it may be recycled to the testing of other hypotheses.
Journal ArticleDOI
Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease — results from a randomized trial programme
Peter Malfertheiner,L. Zeijlon,Pentti Sipponen,S Veldhuyzen van Zanten,Carl-Fredrik Burman,Tore Lind,M. Wrangstadh,Ekkehard Bayerdörffer,J. Lonovics +8 more
TL;DR: It is shown that Helicobacter pylori infection has been proposed as a protective factor against the development of gastro‐oesophageal reflux disease and is associated with good prognosis in women.
Journal ArticleDOI
Are flexible designs sound
Carl-Fredrik Burman,C Sonesson +1 more
TL;DR: It is concluded that flexible design in its most general form with the corresponding weighted test is not valid and several possible modifications of the flexible design methodology are discussed with a focus on alternative hypothesis tests.
Journal ArticleDOI
The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.
Karna Dev Bardhan,Ekkehard Bayerdörffer,Sander Veldhuyzen van Zanten,Tore Lind,Francis Mégraud,Jean Charles Delchier,Magnus Hellblom,A Stubberöd,Carl-Fredrik Burman,Per‐Olof Gromark,L. Zeijlon +10 more
TL;DR: Three different dosages of omeprazole, amoxycillin, and metronidazole were compared, and the influence of metronodazole resistance on eradication was assessed.
Journal ArticleDOI
Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week
John Gregson,Linda D. Sharples,Gregg W. Stone,Carl-Fredrik Burman,Fredrik Öhrn,Stuart J. Pocock +5 more
TL;DR: This review presents real examples of cardiology trials with different types of non-PH: an early treatment effect, a late treatment effect), and a diminishing treatment effect; the relative merits of a Cox model, an accelerated failure time model, a milestone analysis, and restricted mean survival time are examined.